No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
長時間作用性β2刺激薬・オロダテロールのCOPD に対する臨床的有用性
Rent:
Rent this article for
JPY
Abstract
Olodaterol, a once︱daily, long︱acting beta2︱agonist(LABA), has recently been regulatory approved overseas with indication of chronic obstructive pulmonary disease(COPD). It has the pharmacological features of high intrinsic activity in addition to selectivity and affinity for the beta2-adrenergic receptor. Various phaseⅢ clinical trials have shown the high effectiveness of olodaterol in patients with COPD, as well as its excellent clinical benefits including safety comparable to that of placebo. Olodaterol was developed as an inhalation medication to be administered by Respimat. In Japan, future therapeutic contribution of olodaterol is expected mostly in combination with tiotropium, whose clinical benefit has already been established in the treatment of COPD.
Full text loading...
/content/article/0386-3603/43080/1109